• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates

Otsuka Holdings

Pharma’s top 20 R&D spenders in 2020

May 13, 2021 By Brian Buntz

The past year has been an unprecedented time for the pharmaceutical industry. On the one hand, the pandemic resulted in substantial delays to clinical trials while also forcing sponsors to rethink clinical trial design to protect participants. But on the other hand, the pandemic underscored the importance of the pharma industry in society.  While the […]

Filed Under: Featured, Pharmaceutical, Research & Development Tagged With: AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, H. Lundbeck, Incyte, Janssen, Merck, Novartis, Otsuka Holdings, Pfizer, Regeneron Pharmaceuticals, Roche, Roche Group, Roche Pharmaceuticals, Sumitomo Danippon Pharma, UCB, Vertex Pharmaceuticals

Pandemic forces Proteus into bankruptcy

June 16, 2020 By Nancy Crotti

Proteus Digital Health has filed for Chapter 11 bankruptcy protection, noting that its efforts to raise money or sell the company fell victim to the COVID-19 pandemic. The Redwood City, Calif.-based company missed a $100 million funding target in December. Once valued at $1.5 billion, Proteus previously raised $420 million from investors including Novartis Venture […]

Filed Under: Business/Financial News, Cardiovascular, Digital Health, Drug-Device Combinations, Featured, Legal News, Mergers & Acquisitions, Pharmaceutical Tagged With: Otsuka Holdings, Proteus Digital Health, Robert Bosch North America, Romaco North America, Xcelience

FDA clears Verily Study Watch for additional capabilities

January 22, 2020 By Chris Newmarker

Verily, Google’s life science’s sister company under Alphabet (NSDQ:GOOGL), has received an FDA 510(k) clearance to include an irregular pulse monitor in its Study Watch wearable. The FDA announcement, last updated Jan. 20, did not include additional information. The agency cleared ECG capabilities on the Study Watch in January 2019. Launched in April 2017, the Study […]

Filed Under: 510(k), Clinical Trials, Digital Health, Featured, Food & Drug Administration (FDA), Patient Monitoring, Pharmaceutical, Regulatory/Compliance Tagged With: Alphabet (Google), Novartis, Otsuka Holdings, Pfizer, Sanofi, Verily

Proteus pivots, hands digital mental health adherence business to Otsuka

January 16, 2020 By Danielle Kirsh

Proteus Digital Health is abandoning its mental illness and cardiovascular work in its digital pill technology after its deal with Otsuka Pharmaceutical (TYO:4578) ended prematurely and will start to focus more on therapeutic areas, STAT News reports. Otsuka Pharmaceutical had been paying Proteus to develop a portfolio of digital medicines for serious mental health conditions. […]

Filed Under: Business/Financial News, Digital Health, Featured, Funding Roundup, Pharmaceutical Tagged With: Otsuka Holdings, Proteus Digital Health

Proteus Digital Health restructuring amid reported funding woes

December 9, 2019 By Nancy Crotti

Proteus Digital Health said today that it is restructuring, reportedly because it failed to close a $100 million funding round. A report by CNBC said the Redwood City, Calif.-based company missed the funding target. Once valued at $1.5 billion, the company previously raised $420 million from investors including Novartis Venture Fund and Kaiser Permanente Ventures, […]

Filed Under: Business/Financial News, Digital Health, Featured, Pharmaceutical Tagged With: Otsuka Holdings, Proteus Digital Health

Otsuka inks collab deal to bring Abilify Mycite drug-device combo to US

August 30, 2018 By Fink Densford

Otsuka Pharmaceutical (TYO:4578) said today it inked a collaborative deal with health management group Magellan Health to distribute its drug-device combo Abilify Mycite in the US. The Tokyo-based pharmaceutical company touted the Abilify Mycite system as the first FDA-approved drug-device combo designed to track drug ingestion, and said that the tracking data will be integrated into […]

Filed Under: Business/Financial News, Distribution, Drug-Device Combinations, Neurological Tagged With: Otsuka Holdings

The 10 most innovative medical devices of 2018

August 3, 2018 By Danielle Kirsh

The nominees for the best medical technology of 2018 were recently announced for the 12th Annual Prix Galien USA Awards. The host of the awards, The Galien Foundation, awards the Prix Galien Award annually to examples of outstanding biomedical and technology product achievements that are designed to improve human condition. Before the candidates can qualify […]

Filed Under: Diabetes, Diagnostics, Digital Health, Drug-Device Combinations, Imaging, Neurological, Patient Monitoring Tagged With: Abbott, Boston Scientific, BrainScope, Foundation Medicine, Integra LifeSciences, Koning Corp., MedTech, Medtronic, Otsuka Holdings, The Galien Foundation

Otsuka to acquire renal denervation firm ReCor Medical

July 10, 2018 By Brad Perriello

Otsuka Holdings (TYO:4578) said today that it plans to acquire the remaining stake it doesn’t already own in ReCor Medical and the renal denervation device it’s developing to treat hypertension. Tokyo-based Otsuka led ReCor’s $15 million Series D in April 2015 to back Palo Alto, Calif.- and Amsterdam-based ReCor’s Radiance-HTN study, which will test its Paradise system in patients […]

Filed Under: Mergers & Acquisitions, Ultrasound, Wall Street Beat Tagged With: Hypertension, Otsuka Holdings, ReCor Medical, Renal

Otsuka Holdings to shift ReCor rights to medical device subsidiary

November 14, 2017 By Fink Densford

Otsuka Holdings said this week it plans to move renal denervation assets it acquired commercialization rights it acquired last year to its wholly-owned subsidiary, Otsuka Medical Devices. The Japan-based company acquired the rights to commercialize ReCor Medical’s renal denervation technology last May after having invested in the company in 2014. Otsuka said that its board […]

Filed Under: Business/Financial News Tagged With: Otsuka Holdings

FDA approves first pill with sensor to track ingestion

November 14, 2017 By Sarah Faulkner

The FDA today approved Abilify MyCite, the first drug in the U.S. to have an ingestible sensor embedded within the pill that can track if the medication was taken. The drug-device combination product is indicated for the treatment of schizophrenia, acute treatment of manic and mixed episodes linked with bipolar I disorder and as an […]

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Neurological, Patient Monitoring, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Otsuka Holdings, Proteus Digital Health

Injectable, extended-release bipolar drug wins FDA nod

July 31, 2017 By Sarah Faulkner

Otsuka Pharmaceutical (TYO:4578) and Lundbeck said last week that its extended-release injectable aripiprazole suspension, Abilify Maintena, won FDA approval as a maintenance monotherapy for adults with bipolar I disorder. The once-monthly intramuscular formulation was created by Otsuka and co-developed and commercialized with Lundbeck, the companies reported. Get the full story at our sister site, Drug Delivery Business News.

Filed Under: Food & Drug Administration (FDA), Neurological, Pharmaceutical, Regulatory/Compliance, Wall Street Beat Tagged With: Lundbeck, Otsuka Holdings

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

DeviceTalks Weekly

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS